FRAX486 is an inhibitor of PAK that is currently under investigation as a potential treatment for schizophrenia; it exhibits neuroprotective activity and anti-psychotic potential. In vitro, FRAX486 ameliorates synaptic deterioration induced by DISC1 knockdown. In animal models of fragile X syndrome, FRAX486 rescues seizures and other behavioral abnormalities.
| Cas No. | 1232030-35-1 |
|---|---|
| Purity | ≥98% |
| Formula | (C25H23Cl2FN6O)2 • H2O |
| Formula Wt. | 522.40 |
| Solubility | DMSO 22 mg/mL (42.85 mM) Water Insoluble Ethanol Insoluble |
| Appearance | Yellow powder |
| Store Temp | 4°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Hayashi-Takagi A, Araki Y, Nakamura M, et al. PAKs inhibitors ameliorate schizophrenia-associated dendritic spine deterioration in vitro and in vivo during late adolescence. Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):6461-6. PMID: 24706880.
Dolan BM, Duron SG, Campbell DA, et al. Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486. Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5671-6. PMID: 23509247.
